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We developed and validated a measurement instrument (CLASI—Cutaneous Lupus Erythematosus Disease Area
and Severity Index) for lupus erythematosus that could be used in clinical trials. The instrument has separate
scores for damage and activity. A group of seven American Dermato-Rheumatologists and the ‘‘American College
of Rheumatology Response Criteria Committee on SLE (systemic lupus erythematosus)’’ assessed content validity.
After a preliminary session, we conducted standardized interviews with the raters and made slight changes to the
instrument. The ﬁnal instrument was evaluated by ﬁve dermatologists and six residents who scored nine patients
to estimate inter- and intra-rater reliability in two sessions. Consultation with experts has established content
validity of the instrument. Reliability studies demonstrated an intra-class correlation coefﬁcient (ICC) for inter-rater
reliability of 0.86 for the activity score (95% conﬁdence interval (CI)¼ 0.73–0.99) and of 0.92 for the damage score
(95% CI¼ 0.85–1.00). The Spearman’s q (Sp) for intra-rater reliability for the activity score was 0.96 (95% CI¼ 0.89 to
1.00) and for the damage score Sp was 0.99 (95% CI¼ 0.97–1.00). Clinical responsiveness needs to be evaluated in a
prospective clinical trial, which is ongoing.
Key words: clinical trial/cutaneous lupus erythematosus/discoid lupus erythematosus/outcome instrument/sub-
acute lupus erythematosus
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Characteristic inflammatory skin changes are seen in a large
majority of individuals with systemic lupus erythematosus
(SLE); however, the cutaneous manifestations of lupus ery-
thematosus (LE) are among the least systematically studied
aspects of these autoimmune illnesses. This has resulted in
part from the lack of validated tools to determine the impact of
therapy on the activity of the cutaneous manifestations of LE.
Disease Activity Measurements
for Skin Disease
During the last three decades there have been numerous
attempts to develop instruments to measure skin disease.
As a good approximation of the available scores, the Med-
ical Algorithm Project lists 108 medical algorithms in der-
matology (www.medal.com, accessed 09/15/2004), the
majority of which are scores to assess clinical disease. Un-
fortunately, most of the developed scores are disease-spe-
cific. There are some general scores, like the Dermatology
Index of Disease Severity (DIDS) (Faust et al, 1997), but they
are too crude in their assessment of body surface area to be
useful for diseases like acne or cutaneous lupus erythe-
matosus (CLE), which only affect relatively small areas of
the skin (Williams, 1997).
In a recent retrospective study, Parodi et al (2000) noted
that 60 measures of SLE were available, but only three of
these appeared useful for dermatologists. Based on their
experience with 176 patients with CLE, Parodi et al (2000)
found even these scores inadequate for dermatologists and
called for revision.
In order to facilitate future clinical trials, we decided to
develop an outcome instrument for CLE.
Results
Literature review A more extensive review of the literature
than is possible within the format of this paper will be pub-
lished by the American College of Rheumatology Sub-
committee on Response Criteria for CSLE.1 Other important
Abbreviations: CLASI, Cutaneous Lupus Erythematosus Disease
Area and Severity Index; CLE, cutaneous lupus erythematosus;
DLE, discoid lupus erythematosus; ICC, intra-class correlation co-
effecient; LE, lupus erythematosus; SLE, systemic lupus erythe-
matosus
The study was conducted at the Department of Dermatology,
University of Pennsylvania.
1Mosca M, Lockshin M, Schneider M, et al: ACR Response
criteria for cutaneous lupus erythematosus in clinical trials, sub-
mitted.
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considerations for the design of the CLASI (Cutaneous
Lupus Erythematosus Disease Area and Severity Index)
were ease of administration and non-reliance on invasive
test.
Separate measurements of disease activity and dam-
age The differentiation between activity and damage within
the CLASI is unusual for dermatological scores, but estab-
lished for scores of SLE. This separation leads to two
scores for each patient. The alternative summary of the re-
sults in one total score would lead to implausibly stable
results for scarring forms of lupus, as activity decreases and
damage becomes apparent. As a result, a summary score
may remain stable, whereas the clinical picture shifts com-
pletely. In addition, because either current activity or dam-
age may have an important impact on the patient’s quality
of life and self-esteem, separate scores are calculated.
Area The CLASI describes the extent of disease in terms
of the intensity of involvement of anatomical areas but
does not record the percentage of body surface area or the
number of lesions. Other scores like Psoriasis Area and
Severity Index (PASI) or SCORAD (SCORing Atopic Derma-
titis) depend heavily on assessment of the skin area, but this
assessment has repeatedly been shown to be hard to re-
produce (Tiling-Grosse and Rees, 1993; Charman et al,
1999; Charman and Williams, 2000). Because CLE, like
guttate psoriasis, involves only small proportions of the
skin, area assessment is even more difficult than in atopic
dermatitis or plaque psoriasis (Ramsay and Lawrence,
1991). Lesion counting, commonly used for acne, is not a
suitable alternative, because the reliability of the lesion
counting is not necessarily better (Lucky et al, 1996) and the
lesions of CLE have widely varying size and may be con-
fluent. Consequently, improvement may lead to divisions of
large lesions into smaller lesions, which would lead to a
paradoxical increase of the score.
Erythema Our testing of the CLASI showed that activity
scores were based largely on the extent of erythema. Ery-
thema is a prominent, easily recognized, and clear-cut
symptom of disease activity. It can be assessed reliably
even on black skin. The clinical assessment of erythema
has been compared to measurement of erythema by in-
struments, e.g., Doppler flowmeter, and visual assessment
has been found to correspond well to the results with these
‘‘objective techniques’’ (Lahti et al, 1993; Quinn et al, 1993).
Associated symptoms Self reporting of symptoms is
common in rheumatic diseases (Rider et al, 1997). For ex-
ample, fatigue has been shown to be a critical factor in
determining quality of life among SLE patients (Hochbert
et al, 1990; Hanly, 1997). We did not integrate these asso-
ciated symptoms into the score, because their relationship
to the physician-assessed symptoms is unclear and we
think they are best reported separately. Separation of re-
ported and assessed symptoms is also used for other
scores, e.g., the SCORAD (1993; Charman and Williams,
2000) and the Leicester score for atopic dermatitis (Berth-
Jones et al, 1995). Results of the scores in clinical trials
should be presented in terms of percentage change, as the
most appropriate description (Farrar et al, 2003). Formal
assessment of the associated symptoms is currently being
conducted within a study to evaluate clinical responsive-
ness of the instrument.
Content validity Content validity and face validity were
confirmed according to the above protocol. Where appro-
priate, changes were made in accordance with the sug-
gestions.
Patients The patients were volunteers from the outpatient
clinic of the department of dermatology of the University of
Pennsylvania, which is a tertiary care center. The nine pa-
tients represent a full range of activity and damage, based
initially on clinical impression, and subsequently confirmed
by calculation of activity and damage scores. Their mean
activity score ranged from 10.1 to 40 and the mean damage
score ranged from 0.7 to 41.6 (Table I).
Inter-rater agreement Inter-rater reliability was high (Table
II). The correlation coefficients between pairs of raters
ranged from rp¼0.82 to rp¼0.99, indicating that the relative
ordering of the patients based on the raters’ scores are
consistent between raters. In addition to high consistency
among raters, the agreement among the raters’ scores for a
given patient is also high. The intra-class correlation coef-
ficient (ICC) was r¼0.86 (95% confidence interval
Table I. CLASI scores of participating patients
SLE type Raters (N)
Activity score Damage score
Mean/median Mean/median
1 SCLE 9 13.3/13.5 13.8/15.5
2 DLE 9 10.1/10 15.6/15.5
3 DLE 9 36.6/39 40.4/40.5
4 DLE 9 17.4/17.5 19.5/19
5 SCLE 9 13.5/13.5 1.9/2
6 SCLE 8 13/13.5 11.8/10.5
7 SCLE 8 12/11 0.7/0
8 DLE 8 18.2/17.5 11.8/12.5
9 DLE 8 40/37.5 41.6/42
CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity
Index; SLE, systemic lupus erythematosus; SCLE, subacute lupus ery-
thematosus; DLE, discoid lupus erythematosus.
Table II. Results of reliability testing
Rater (n) Patients (n)
Inter-rater reliability ICC
Activity 11 9 0.86 (95% CI¼0.73–0.99)
Damage 11 9 0.92 (95% CI¼0.85–1.00)
Intra-rater reliability Spearman’s r
Activity 8 4 0.96 (95% CI¼0.89–1.00)
Damage 8 4 0.99 (95% CI¼0.97–1.00)
ICC, Intraclass Correlation Coefficient; CI, confidence interval.
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(CI)¼0.73–0.99) for the activity scale and r¼0.92 (95%
CI¼ 0.85–1.00) for the damage scale. In addition, the ANO-
VA results do not show significant differences among the
raters’ overall scores (the activity F test¼0.32, p¼ 0.97; the
damage score F test¼0.32, p¼ 0.97), whereas there were
significant differences in overall scores among the patients
(the activity score F test¼52.01, po0.0001; the damage
score F test¼ 105.64, po0.0001).
Intra-rater reliability Both scales demonstrated high intra-
rater reliability (Table II). The differences between first and
second rating for the activity subscale ranged from 1 to 4
points of 13 to 15 point total score, but the mean difference
between first and second rating was only 2.0 points on av-
erage. Slightly higher ratings were given on the second rating
by 90% of the raters. Although the difference between the
first and second rating in the activity scale was statistically
significant (t¼2.57; po0.03), this difference is clinically
meaningless. The differences between ratings for the damage
scores were even smaller and ranged from 0 to 2 points, with
a mean of 0. Four of the eight pairs of ratings were identical,
two raters increased by 1 or 2 points, and two raters de-
creased by 1 or 2 points. The difference between ratings in
the damage score did not reach statistical significance
(t¼ 0.00; p¼1.0). Both scales also demonstrated high con-
sistency throughout regarding the relative ordering of the pa-
tients at first and second rating. There were no outliers. These
results were reflected in an Spearman’s r (Sp) of rp¼ 0.96 for
activity (95% CI¼0.89–1.00) and an Sp of rp¼0.99 (95%
CI¼ 0.97–1.00) for the damage scale. The intercept and slope
of the regression equation relating 1st scores to second
scores show small differences for both subscales (i.e., inter-
cepts of 2 for activity and 0 for damage), and a slope close to
1, (b¼0.73 for activity and b¼ 0.89 for damage) for predicting
the second rating based on the result of the 1st rating.
Time The average time needed to conduct the patient as-
sessment with the CLASI ranged from less than 1 min to 11
min with an average duration of 5.25 min and a median of 5
min; we did not find any significant variation over time as the
experience with the instrument increased.
Discussion
As a first effort toward validating an outcome instrument for
CLE, we assessed the CLASI for content validity, inter-rater
validity, intra-rater validity, and practical applicability. The
score performed excellently in all these aspects, which is
especially relevant for multicenter studies that form the
backbone of any therapeutic evaluation for this rare dis-
ease. It is also notable that the CLASI has not been devel-
oped within the framework of a particular clinical trial,
because it has been suggested that instruments developed
for a particular trial might bias the trial in favor of the treat-
ment. This kind of effect has been demonstrated for schiz-
ophrenia (Charman and Williams, 2000).
The CLASI has been designed as one single instrument
for at least three clinical entities that constitute CLE, i.e.,
discoid lupus erythematosus (DLE), subacute lupus erythe-
matosus (SCLE), and SLE. We think that the limitation to
one instrument for CLE is necessary and appropriate. There
are a number of CLE cases that may share characteristics
of two or even all three groups of CLE. Although pure pa-
tient populations are always desirable, they do not reflect
clinical reality. In an orphan disease like LE, an instrument
that improves the power of clinical research is not helpful if it
restricts the population to subgroups that cannot realisti-
cally be recruited for even medium-sized clinical trials.
CLE affects primarily photosensitive areas like the face,
neck, and hands. Skin symptoms in these uncovered and
thus visible areas are more worrisome to patients (Baugh-
man and Sobel, 1970; Nichol et al, 1996; Williams, 1997;
Krueger et al, 2001). To increase the score’s responsiveness
we have increased the weight assigned to these symptoms,
relative to other, less frequently involved parts of the body.
This may skew the score slightly away from a purely ana-
tomical reflection of the skin surface. We think this choice is
clinically appropriate, however, and may actually be more
meaningful to both patient and clinician because it takes the
non-linear association between score and severity into ac-
count (Ashcroft et al, 1999). The table below compares the
percentage of the score derived from different areas of the
body between the CLASI, the PASI, and the rule of 9’s (Table
III). The rule of 9’s, a method of estimating surface area
based on attributing a given percentage to each body part,
is used to estimate involved body surface area, e.g., in
psoriasis (Ramsay and Lawrence, 1991).
Finlay (1996) defined desirable criteria for an instrument
to measure disease activity in atopic dermatitis, which are
general enough to be helpful to assess the CLASI:
(1) The method should be simple enough to use in a busy
clinical setting.
(2) The method should clearly separate scores derived from
the observer and from the patient.
(3) The signs chosen to be recorded should be amenable to
change and should be unambiguous in their meaning
and proven to be so. If the presence of two signs is
highly correlated only one needs to be recorded.
(4) Recording of area of involvement should be based on an
assessment of the site of involvement rather than the
virtually impossible task of determining an accurate total
percentage involvement.
(5) Validity testing including repeatability testing by the
same and different observers must be carried out.
Table III. Relative weight of body area for CLASI, PAST and
rule of q
Area
CLASI (activity
and damage) (%) PASI (%)
Rule
of 9 (%)
Head 33 10 9
Chest 14 5 9
Abdomen 7 5 9
Back 14 10 18
Legs 14 40 36
Arms/hands 14 30 18
Mucous membrane 1
CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity
Index; PASI, Psoriasis Area and Severity Index.
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Select the score in each anatomical location that describes the most severely affected cutaneous lupus-associated lesion 
Anatomical Location Erythema         Scale/ Hypertrophy Dyspigmentation 
Scarring/ 
Atrophy/   
Panniculitis 
 Anatomical Location 
0-absent 
1-pink; faint erythema 
2- red;  
3-dark red; 
purple/violaceous/ 
crusted/ hemorrhagic 
0-absent;  
1-scale  
2-verrucous/ 
hypertrophic 
0-absent, 
1-dyspigmentaton  
0 … absent 
1 … scarring 
2 … severely 
atrophic scarring 
or panniculitis
Scalp See below Scalp 
Ears Ears 
Nose (incl. malar area) Nose (incl. malar area) 
Rest of the face  Rest of the face  
V-area neck (frontal) V-area neck (frontal) 
Post. Neck &/or shoulders Post. Neck &/or shoulders 
Chest Chest 
Abdomen  Abdomen  
Back, buttocks Back, buttocks 
Arms   Arms   
Hands Hands 
Legs Legs 
Feet Feet 
Mucous membrane Dyspigmentation
Mucous membrane lesions (examine if patient confirms involvement)  Report duration of dyspigmentation after active lesions have resolved (verbal report by patient … tick appropriate box)  
0-absent;  
1-lesion or ulceration
 Dyspigmentation usually lasts less than 12 months (dyspigmentation  
score above remains) 
 Dyspigmentation usually lasts at least 12 months (dyspigmentation 
score is doubled)
Alopecia
Recent Hair loss  
(within the last 30 days/as reported by patient)
1-Yes 
0-No
Divide the scalp into four quadrants as shown. The dividing line between right and left is the midline. The dividing line between frontal and occipital 
is the line connecting the highest points of the ear lobe. A quadrant is considered affected if there is a lesion within the quadrant. 
Alopecia (clinically not obviously scarred) Scarring of the scalp (judged clinically) 
0-absent 
1-diffuse; non-inflammatory 
2-focal or patchy in one quadrant; 
3-focal or patchy in more than one quadrant 
0- absent 
3- in one quadrant  
4- two quadrants 
5- three quadrants 
6- affects the whole skull 
Total Activity Score Total Damage Score 
(For the activity score please add up the scores  (For the damage score, please add up the scores 
of the left side i.e. for Erythema, Scale/Hypertrophy,        of the right side, i.e. for Dyspigmentation, 
Mucous membrane involvement and Alopecia) Scarring/Atrophy/Panniculitis and Scarring  
of the Scalp)  
damage activity 
E
x
t
e
n
t 
NB: if scarring and non-scarring aspects seem
to coexist in one lesion, please score both
Figure 1
Cutaneous LE Disease Area and Severity Index (CLASI)
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We believe that the CLASI fulfills the above criteria and is
thus an appropriate instrument to assess the activity and
damage caused by CLE. We hope, therefore, that it will be
used in clinical trials of CLE. Preliminary findings indicate
that the instrument has sufficient clinical responsiveness to
be useful for clinical trials and formal assessment of these
properties in clinical trials is forthcoming.
Materials and Methods
Literature review The design of the CLASI and its characteristics
are based on a review of the literature on LE and outcome instru-
ments used in dermatology. The most significant results of this
review are presented in the results section.
Scoring of the CLASI (Fig 1) The CLASI consists of two scores,
the first summarizes the activity of the disease, whereas the sec-
ond is a measure of the damage done by the disease. Activity is
scored on the basis of erythema, scale/hyperkeratosis, mucous
membrane involvement, acute hair loss, and non-scarring alo-
pecia. Damage is scored in terms of dyspigmentation and scarring,
including scarring alopecia. Patients are asked whether dyspig-
mentation due to CLE lesions usually remains visible for more than
12 mo, which is taken to be permanent. If so, the dyspigmentation
score is doubled. The scores are calculated by simple addition
based on the extent of the symptoms. The CLASI is designed as a
table where the rows denote anatomical areas, whereas the col-
umns score major clinical symptoms. The extent of involvement for
each of the skin symptoms is documented according to specific
anatomic areas that are scored according to the worst affected
lesion within that area for each symptom.
Associated symptoms Itch, pain and fatigue are recorded sep-
arately on visual 1–10 analog scales by the patients.
Assessment of content validity The instrument was assessed in
informal interviews and email exchanges, by a group of 7 US Der-
mato-Rheumatologists, all of whom have considerable expertise
with CLE and gave valuable feedback. We also solicited comments
from the ‘‘American College of Rheumatology Response Criteria
Committee on SLE’’, which consists of Rheumatologists and Der-
matologists, in a session at Schloss Mickeln, Duesseldorf, Ger-
many, in September of 2004. Additionally, we conducted a series of
extensive standardized interviews with the raters to the point of
redundancy after the assessment of the previous version of the
score, in order to establish areas for improvement, mostly con-
cerning the wording of the instrument.
Assessment of inter- and intra-rater reliability Inter-rater relia-
bility was assessed by a group of 11 physicians (five board-cer-
tified dermatologist and six second- or third-year resident
physicians) who scored a group of nine patients according to a
predefined protocol in two sessions. In the first session, five pa-
tients were scored by nine physicians and in the second session,
four patients were scored by eight physicians. Of the total of 11
scoring physicians, six scored all nine of the patients, three scored
five patients, and two scored four patients. All physicians recorded
the time they spent in each patient’s room.
To assess intra-rater reliability, eight of 11 physicians (five
board-certified dermatologist and three second- or third-year res-
ident physicians) scored four of the nine patients. These patients
also represented a wide range of activity levels (scores ranged
from a mean of 11.9 to a mean of 17.8) and damage levels (be-
tween a mean of 0.8 and a mean of 11.9). In order to minimize
recall, the physicians were not told at the beginning of the session
that one additional patient had to be scored a second time at the
end of the session to assess the intra-rater reliability.
Patients Nine patients were scored for this study. All had histo-
logically confirmed CLE. Five of the patients had DLE and four
SCLE; two of the patients, one with SCLE and one with DLE, had
systemic involvement.
Statistical methods/hypothesis We assessed the inter- and in-
tra-rater reliability of the CLASI based on the two directly calcu-
lated subscale scores for activity and damage.
To assess inter-rater reliability we used the ICC, Pearson cor-
relations, and ANOVA. The ICC was calculated using STATA (Ver-
sion 8). An ICC of 0.5–0.7 was considered minimally acceptable,
whereas an ICC above 0.81 is considered to be almost perfect
(Landis and Koch, 1977). We had originally planned to use six ra-
ters with eleven patients per rater, which would have given us ad-
equate power (80%) to detect an intra-class correlation based on a
null hypothesis of an ICC of 0.5 and an alternative hypothesis of an
ICC of 0.8 using an F test with a significance level of 0.05. Because
fewer patients than expected could be recruited at any one time
and the CLASI performed better than expected during the prelim-
inary and first session, the final numbers of participants were a
compromise to what had been originally planned. An ANOVA was
used to test for general ‘‘rater effects’’.
To describe the magnitude and direction of the change in the
patients’ scores from first rating to 2nd rating of the same patients
at the same session, summary statistics were calculated. To as-
sess intra-rater reliability, we used correlations (Pearson and Sp),
regressions, and t tests. Although we recognize the inherent weak-
ness of the simple linear correlation as a measure of agreement,
we report this in recognition of its common use as a measure of
intra- and inter-rater reliability (Walter et al, 1998).
Ethics The protocol for the study was approved by the institu-
tional review board of the University of Pennsylvania Medical
School and is in accordance with the Declaration of Helsinki in its
current form. All patients gave written consent before inclusion in
the study.
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